What question did this study set out to answer?

The aim is to report a rare instance of torsades de pointes related to levetiracetam use.

March 1, 2026Journal of current cardiology.0 citations

Levetiracetam-induced torsades de pointes: An anomalous status

RMRanjan ModiFortis Escorts Hospital RSRajender SinglaFortis Escorts Hospital

Key Result

Levetiracetam can induce torsades de pointes (TDP), evidenced by a 59-year-old female requiring multiple cardioversions after its administration.

Key Points

The aim is to report a rare instance of torsades de pointes related to levetiracetam use.
Documented a case involving a 59-year-old female patient.
Monitored the patient's cardiac rhythm following levetiracetam administration.
Treated multiple episodes of torsades de pointes with electric cardioversions.
Observed multiple instances of torsades de pointes post-levetiracetam therapy.
Noted that this is among the few documented cases worldwide.
Findings highlight a previously underestimated cardiac risk associated with levetiracetam.

Structured PICO

Population

1 59-year-old female

Intervention

Levetiracetam

Outcome

Occurrence of Torsades de pointes (TDP)safety

Highlights a rare but severe adverse event of torsades de pointes associated with levetiracetam use.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract: Torsades de pointes (TDP) is a result of prolonged QTc interval, which may be due to congenital and acquired factors. Levetiracetam is a commonly prescribed anti-epileptic drug and has a highly favorable safety profile. Here, we report the unique occurrence of TDPs leading to multiple electric cardioversions in a 59-year-old female following the administration of levetiracetam. As far as we know, there is only very few previous documented case of TDPs occurring after levetiracetam and none in the Indian subcontinent.

AI से पूछें

Bookmark

View Full Paper